Supercharging a New FDA: Marty Makary on Science, Power & Patients - All-In Podcast Recap

Podcast: All-In Podcast

Published: 2026-01-15

Duration: 1 hr 30 min

Guests: Marty Makary

Summary

FDA Commissioner Marty Makary has introduced 42 major reforms in an effort to streamline drug approvals and increase transparency in healthcare. The episode covers the FDA's strategies to modernize, reduce drug costs, and tackle America's obesity epidemic.

What Happened

Marty Makary, the FDA Commissioner, has spearheaded a significant overhaul at the agency, implementing 42 major reforms within his first 10 months. This includes initiatives to reduce the drug approval timeline from 10-12 years by adopting new programs and encouraging transparency, such as making rejection letters public to ensure accountability. The FDA is also addressing the global biotech competition, recognizing China's increasing dominance in scientific publication and licensing deals, which necessitates a strategic response from the U.S. biotech sector.

Makary highlights the aim to cut down drug approval time by reducing the requirement from two pivotal trials to one and employing AI to expedite supplemental application reviews from 60 days to one day. He is also focused on modernizing drug testing by reducing animal testing and using technologies like computational modeling and organ-on-a-chip.

The episode touches on the FDA's efforts to reform nutritional guidelines, criticizing the previous food pyramid's emphasis on carbohydrates. The updated guidance now focuses on increasing protein intake to combat the high prevalence of pre-diabetes and diabetes among American children, where currently, 60-70% of their calories come from refined carbohydrates.

Makary discusses the obesity epidemic in America, with GLP-1 drugs being tested for multiple health benefits, and the broader effort to reduce drug prices through faster biosimilar approvals and increasing availability of over-the-counter options.

Vaccination schedules have been revised, reducing the number of core essential doses from 72 to 38 in an attempt to improve vaccination rates. There is also a push to ensure medications are more affordable, with Makary pointing out the stark price differences for drugs like GLP-1 between the U.S. and other countries.

The episode concludes with a discussion about the FDA's role in regulating pharmaceutical advertising to prevent misleading claims and the potential of AI in healthcare, highlighting the need for the FDA to adapt to rapidly evolving technological advancements.

Key Insights

• The FDA has reduced the drug approval timeline by allowing one pivotal trial instead of two and using AI to cut supplemental application reviews from 60 days to one day.
• Updated nutritional guidelines now prioritize increased protein intake over carbohydrates to address the high rates of pre-diabetes and diabetes in American children, where 60-70% of their calories are from refined carbohydrates.
• The number of core essential vaccine doses has been reduced from 72 to 38 to improve vaccination rates, while efforts continue to make medications more affordable by addressing price disparities.
• GLP-1 drugs are being tested for multiple health benefits as part of a broader strategy to address the obesity epidemic and reduce drug prices through faster biosimilar approvals and increased over-the-counter options.